The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga.
Verdemed, a Canadian pharmaceutical cannabis company, is on a mission to bring medicinal cannabis to Latin America.
As the studies on the effects of medicinal cannabis continue to grow, it’s benefits are becoming more well-known. Verdemed works to make these pharmaceuticals more accessible to other parts of the world, specifically Latin America.
Verdemed’s Managing Director, Fabio Lampu Gnani, and its Head of Legal Affairs, Werner Buff, will be speaking at Benzinga’s upcoming Virtual Cannabis Conference.
The pair will be presenting an overview of the company along with an investment opportunity for attendees.
“Latina American market is an uneven and heterogeneous landscape, where some countries already regulated medicinal and pharmaceutical cannabis and some others are at an inflection point of their regulatory framework that will unlock real opportunities,” said Lampu Gnani.
Starting at the beginning of 2020, Verdemed expanded its platform and sales to Brazil. And now, the company is expanding its business to Chile and Peru.
The company’s plans for the future are to register two pharmaceutical products in Brazil and in Peru within the third quarter of 2020.
To learn more about Verdemed, you can sign up for Benzinga’s Virtual Cannabis Capital Conference by clicking here.
The preceding post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Although the piece is not and should not be construed as editorial content, the sponsored content team works to ensure that any and all information contained within is true and accurate to the best of their knowledge and research. This content is for informational purposes only and not intended to be investing advice.
The greatest investors and entrepreneurs in Cannabis are gathering in New York City this Fall! Don't miss out.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.